Literature DB >> 31385765

Methotrexate overdose in clinical practice.

Ashok Kumar Pannu1.   

Abstract

BACKGROUND: A folic-acid antagonist, methotrexate, is one of the most commonly prescribed drugs with its expanding use in clinical practice. The drug requires regular monitoring given its wide range of adverse effects including bone marrow suppression, hepatic or renal dysfunction, gastrointestinal distress, mucocutaneous damage, and neurotoxicity. The toxicity usually occurs rapidly and leads to severe neutropenia, sepsis, and advanced renal failure that are difficult to manage.
METHODS: This review is an update for the clinicians to understand the pharmacology, clinical features, laboratory evaluation, and treatment of patients with methotrexate overdose. High-quality literature of the past six decades was collected and reviewed in this article. Several landmark articles were reviewed using PubMed, EMBASE Ovid, and the Cochrane Library, that have important implications in current clinical practice.
RESULTS: Methotrexate overdose has complex toxicokinetic and produces myriad clinical features mimicking conditions of lesser severity. Organ dysfunction related to bone marrow, kidney or central nervous system is lifethreatening. The management should focus on high-quality supportive care, antidotal therapy (folinic acid and carboxypeptidase- G2) and plasma alkalization.
CONCLUSION: In accordance with the dictum "prevention is better than cure", the author emphasizes on the role of patient education, regular clinical observation, and laboratory monitoring for prompt recognition and diagnosis of methotrexate overdosing at the earliest stage. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Methotrexate; carboxypeptidase-G2; folinic acid; glucarpidase; leucovorin; overdose; poisoning; toxicity.

Mesh:

Substances:

Year:  2019        PMID: 31385765     DOI: 10.2174/1389200220666190806140844

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  6 in total

1.  Early, empiric high-dose leucovorin rescue in lymphoma patients treated with sequential doses of high-dose methotrexate.

Authors:  Jason N Barreto; Kristen T Peterson; Erin F Barreto; Kristin C Mara; Ross A Dierkhising; Nelson Leung; Thomas E Witzig; Carrie A Thompson
Journal:  Support Care Cancer       Date:  2021-03-04       Impact factor: 3.603

2.  [Patient safety in the treatment of rheumatic diseases : Laboratory monitoring in methotrexate treatment].

Authors:  Elizabeth Sierocinski; Aniela Angelow; Armin Mainz; Jochen Walker; Jean-François Chenot
Journal:  Z Rheumatol       Date:  2021-03-11       Impact factor: 1.372

3.  Lack of drug interaction between levetiracetam and high-dose methotrexate in patients with lymphoma.

Authors:  Catherine E DeFino; Jason N Barreto; Amanda G Pawlenty; Michael W Ruff; Ivan D Carabenciov; Kristin C Mara; Carrie A Thompson
Journal:  Pharmacotherapy       Date:  2021-03-16       Impact factor: 6.251

4.  The Application of 99mTc-DTPA Renal Dynamic Imaging to Measuring Renal Function of Children with Acute Lymphoblastic Leukemia after Induction Therapy.

Authors:  Lidan Wang; Kailan Chen; Qiong Xu
Journal:  Biomed Res Int       Date:  2020-11-17       Impact factor: 3.411

Review 5.  Pharmacomicrobiology of Methotrexate in Rheumatoid Arthritis: Gut Microbiome as Predictor of Therapeutic Response.

Authors:  Huanhuan Yan; Rui Su; Hongwei Xue; Chong Gao; Xiaofeng Li; Caihong Wang
Journal:  Front Immunol       Date:  2021-12-16       Impact factor: 7.561

Review 6.  The Therapeutic Landscape of Rheumatoid Arthritis: Current State and Future Directions.

Authors:  Shahin Shams; Joseph M Martinez; John R D Dawson; Juan Flores; Marina Gabriel; Gustavo Garcia; Amanda Guevara; Kaitlin Murray; Noah Pacifici; Maxemiliano V Vargas; Taylor Voelker; Johannes W Hell; Judith F Ashouri
Journal:  Front Pharmacol       Date:  2021-05-28       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.